Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Introduction: Obesity is a complicated chronic disease associated with a series of other conditions. A weight loss of 5–10% has been shown to reduce obesity-related complications and improve quality of life. The efficacy and safety of liraglutide for reducing body weight have been demonstrated in clinical trials. This study evaluated the weight loss efficacy and adverse effects of liraglutide in those with obesity in the Turkish population. Methods: This is a retrospective cohort study; the patients that were included had a body mass index (BMI) of 27 or greater with additional comorbidities or a BMI of 30 or greater, and the patients were prescribed liraglutide for obesity treatment from the tertiary private clinic between January 2022 and January 2024. Their metabolic and anthropometric parameters were recorded at the initial appointment, and their body weight and adverse effects were followed up on during therapy. Results: For the 568 patients, of whom 487 (85.6%) were female, the mean values for age, weight, and BMI were 42.37 ± 10.50, 98.09 ± 17.48 kg, and 35.77 ± 5.45 kg/m2, respectively. Reductions in body weight at the 4th, 8th, 12th, and 24th weeks were 6.45 ± 2.32 kg, 10.66 ± 3.41 kg, 15.38 ± 8.30 kg, and 19 ± 9.06 kg, respectively; reductions in BMI at the 4th, 8th, 12th, and 24th weeks were 2.36 ± 1.00, 3.88 ± 1.25, 5.36 ± 1.76, and 7.09 ± 2.93, respectively; and the percentages of overall body weight loss at the 4th, 8th, 12th, and 24th weeks were 6.62 ± 2.1%, 10.75 ± 2.71%, 14.97 ± 6.8%, and 18.55 ± 4.63%, respectively (all p values < 0.0001). The percentage of patients who lost more than 5% and more than 10% of their initial weight was 100% at the 24th week. The most common side effect was nausea; no pancreatitis was observed. Conclusions: The results of our study indicate that liraglutide is an efficacious and safe treatment option for obesity in the Turkish population, in accordance with the findings from previous research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Importantly, the weight‐loss effectiveness of GLP‐1RA was similar to what has been observed in trials when focusing on the subgroup of adherent patients who consistently took their prescribed GLP‐1RA, for example, at 12 months follow‐up, 50 , 53 , 55 , 56 , 57 , 58 , 61 whereas studies reporting results in an ‘as‐started’ approach found considerably lower effectiveness. 52 , 59 , 63 , 66”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [55]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The observed weight reduction in clinical practice overall tends to be lower than in randomized controlled trials; however, outcomes approach those seen in trials when focusing on highly adherent patients.”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [55]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The percentage weight reduction over typically 6–12 months of follow‐up thus ranged from 2.2% to 18.5% for liraglutide, 52 , 55 4.4% to 19.5% for semaglutide 61 , 65 and 4.8% to 21.2% for tirzepatide. 50 , 59”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [55]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Areas of particular focus are how to avoid selection bias, which is a frequent concern in studies that only include ‘drug survivors’, 53 , 55 , 58 , 60 , 61 , 62 , 65 , 67 , 70 , 71 that is, those retaining treatment over a prolonged period, or those restricting their analyses to high‐dose users. 57”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [55]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432 · cited 1×
“…to the European Guidelines for the Management of Obesity in Adults, pharmacotherapy should be considered as part of a comprehensive disease management strategy and is recommended for adults with a body mass index (BMI) > 30 kg/m 2 or a BMI > 27 kg/m 2 with an obesity-related comorbidity [5].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 8×
“In the liraglutide phase study, the mean BMI of the group receiving liraglutide was 36 ± 5.9 kg, with a change in BMI of 2.1 ± 2 in the group receiving treatment at 56 weeks [10].”
BackgroundMethodInfluentialDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 2×
“The clinical development studies of liraglutide have also been designed with this objective in mind [10,11,18,23].”
BackgroundLau, D. C. W., Douketis, J. D., Morrison, K. M., Hramiak, I. M., Sharma, A. M., Ur, E., & Panel, F. M. O. T. O. C. C. P. G. E. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.061409 · Cited by 1,154 · cited 1×
“…when used in conjunction with lifestyle modifications, is advised to facilitate the alleviation of obesity-related symptoms in adults who are overweight or obese and who are unable to achieve or sustain clinically significant weight loss through dietary and exercise regimens alone [7].”
Backgroundon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 3×
“The clinical development studies of liraglutide have also been designed with this objective in mind [10,11,18,23].”
BackgroundInfluentialGadde (2018) · doi:10.1016/j.jacc.2017.11.011 · Cited by 626 · cited 1×
“The implementation of lifestyle modifications, comprising a reduction in food intake and an increase in physical activity, has not resulted in consistent long-term weight loss due to physiological counter-regulatory mechanisms that are in operation [3,4].”
Backgroundon behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“However, in addition to this metabolic effect, this medication has also demonstrated efficacy as a regulator of appetite [8,9].”
BackgroundEuropean Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care
Durrer Schutz, D., Busetto, L., Dicker, D., Farpour-Lambert, N., Pryke, R., Toplak, H., Widmer, D., Yumuk, V., & Schutz, Y. (2019) · Obesity Facts · doi:10.1159/000496183 · Cited by 492 · cited 1×
“Pharmacotherapy is a noninvasive approach that can help people with obesity adhere to weight loss strategies, improve their quality of life, and reduce the risk of comorbidities [6].”
Background
Research works printed but not linked: 1
- Tor, 2023, Obezitenin Medikal Tedavisinde Liraglutide Etkinliğinin Araştırılması, Sakarya Tıp. Dergisi., 13, 334
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Oral, A., Solmaz, İ., Koca, N., Topaloğlu, U. S., Demir, İ., Dündar, A. S., Kırık, A., BAŞCI, Ö. K., Şen, H., Binnetoglu, E., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082680 · Cited by 8
Self-citationIs liraglutide safe and effective in the elderly obese patients?: A single center experience
Oral, A., Küçük, C., & Kayalar, Y. (2025) · Medicine · doi:10.1097/md.0000000000042155 · Cited by 3
“[23] The mean BMI of our study cohort was 36.49 at the beginning; at 24 weeks, 100% of the patients exhibited weight loss of at least 5% and mean weight reduction was 15.8%.”
InfluentialSelf-citationChen, Y., Du, F., Ospina, N. S., Brito, J. P., Shao, H., Liu, Q., McCoy, R. G., & Jiao, T. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag131 · Cited by 4
Miertová, Z., Lecký, P., Focko, B., Bolek, T., Péč, M. J., Jurica, J., Nagy, N., Galajda, P., Mokáň, M., & Samoš, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-56147-8 · Cited by 2
“In another postmarketing study, Oral et al. 16 examined the anti-obesity effect of liraglutide (short-acting GLP-1 RA) in 568 patients (from whom 487 were women) and found a 19 ± 9.06 kg weight reduction after 24 weeks of therapy (representing a 18.55 ± 4.63% weight reduction), and a weight reduction ≥ 5% was detected…”
Influential
Metadata
- Authors
- Oral, A., Küçük, C., & Köse, M.
- Affiliations
- Biruni University (TR)
- Istanbul University (TR)
- Corresponding author
- Oral, Alihan
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2024-10-14
- Volume
- 13
- Issue
- 20
- Pages
- 6121
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC11508960
- OpenAlex
- W4403605864
- Cited by
- 8
- References
- 23
- Citations by year
- 2026: 4 · 2025: 4
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- liraglutide, obesity, weight loss, GLP-1 receptor agonists, real-world effectiveness, adverse effects, gastrointestinal adverse effects, body mass index, Turkish patients, obesity-related comorbidities, patient satisfaction, quality of life
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study. https://app.cochat.ai/papers/10.3390/jcm13206121
- The paper
- Oral, A., Küçük, C., & Köse, M. (2024). Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study. Journal of Clinical Medicine. https://doi.org/10.3390/jcm13206121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.